 DALLAS--BUSINESS WIRE--- LTRN--Lantern Pharma Inc. NASDAQ: LTRN, a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence A.I. and machine learning M.L. platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will present preclinical data on the potency of Lanterns drug candidate LP-284 for mantle cell lymphoma MCL and several other non-Hodgkins lymphomas at the Society of Hematologic On 